Kaitlyn D’Onofrio

DocwireNews

A study found that patients with relapse-remitting multiple sclerosis (RRMS) are nearly twice as likely than controls to experience olfactory dysfunction. The researchers also identified a correlation between olfactory dysfunction and fatigue in patients with RRMS treated with dimethyl fumarate or fingolimod.Thirty controls and 30 patients with RRMS were compared. Patients with RRMS were treated with either injectable (interferon &beta; or glatiramer acetate, n=18) or oral disease-modifying therapies (dimethyl fumarate or fingolimod, n=12). The Sniffin&rsquo; Sticks Identification Test (SSIT) was used to determine hyposmia, which was defined as a SSIT olfactory test score &le;6 points. Data collection included number of previous relapses, disability in Expanded Disability Status Scale (EDSS), recent MRI scan of the brain, thalamic volume, and third ventricle width. Two years after the olfactory assessment, patients were evaluated for cognition per the Symbol Digit Modalities Test (SDMT) and fatigue per the Fatigue Scale for Motor and Cognitive Functions (FSMC).Patients with RRMS were more likely than controls to have hyposmia (66.7% vs. 36.7%; odds ratio, 1.82; 95% confidence interval, 1.10-3.67; P=0.02). The number of previous relapses; new brain MRI lesions; EDSS, SDMT, and FSMC scores; thalamic volume; and third ventricle width were not associated with SSIT score (P&gt;0.05). Olfactory dysfunction was associated with the FSMC cognitive subscale among patients receiving oral drugs (P=0.006).

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Olfactory Dysfunction Is Associated with Fatigue in Patients with Relapse-remitting MS Receiving Oral Therapies

Multiple Sclerosis

A study found that patients with relapse-remitting multiple sclerosis (RRMS) are nearly twice as likely than controls to experience olfactory dysfunction. The researchers also ...

Olfactory Dysfunction Is Associated with Fatigue in Patients with Relapse-remitting MS Receiving

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe